StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.21 | $0.20 | -3.64% | 2.4M |
| 05-12 | $0.20 | $0.18 | -7.50% | 5.2M |
| 05-13 | $0.19 | $0.20 | +6.78% | 2.4M |
| 05-14 | $0.20 | $0.19 | -3.60% | 4.0M |
| 05-15 | $0.16 | $0.19 | +16.00% | 3.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 |
|---|---|---|
Revenue | $45.00K | $45.00K |
Operating Income | $-23.13M | $-18.44M |
Net Income | $-25.43M | $-17.67M |
EPS (Diluted) | $2.99 | $-2.08 |
Total Assets | $2.60M | $42.16M |
Total Liabilities | $43.44M | $10.37M |
Cash & Equivalents | $590.00K | $300.00K |
Free Cash Flow OCF − CapEx | $-13.64M | $-9.61M |
Shares Outstanding | 8.58M | 4.13M |
No sell-side coverage available for CLDI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CLDI.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.